OmniAb (NASDAQ:OABI – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Earnings & Valuation
This table compares OmniAb and Champions Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OmniAb | $18.67 million | 36.52 | -$64.78 million | ($0.36) | -13.08 |
| Champions Oncology | $59.42 million | 1.16 | -$1.17 million | ($0.08) | -62.04 |
Insider and Institutional Ownership
72.1% of OmniAb shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 9.8% of OmniAb shares are owned by insiders. Comparatively, 47.0% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares OmniAb and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | -115.12% | -16.59% | -14.82% |
| Champions Oncology | -1.87% | -27.48% | -3.84% |
Analyst Recommendations
This is a breakdown of current recommendations for OmniAb and Champions Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 1 | 0 | 2 | 0 | 2.33 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
OmniAb presently has a consensus price target of $11.00, suggesting a potential upside of 133.55%. Given OmniAb’s stronger consensus rating and higher probable upside, research analysts plainly believe OmniAb is more favorable than Champions Oncology.
Risk & Volatility
OmniAb has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.
Summary
OmniAb beats Champions Oncology on 8 of the 14 factors compared between the two stocks.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
